News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Jefferies initiated coverage of Quantinuum stock with a buy rating, touting the company's broad hardware and software platform.
The deal adds navtemadlin—a drug candidate for a rare blood cancer in late-stage clinical trials—to Ipsen’s oncology pipeline.
The committee is recommending that no new patients start treatment with Tavneos and that existing patients be switched to suitable alternatives.
The European Medicines Agency said Friday that its Committee for Medicinal Products for Human Use (C
Amgen Inc. (NASDAQ:AMGN) ranks among the best set-it-and-forget-it stocks to buy right now. On June 12, Piper Sandler reaffirmed its Overweight rating and $427 price target for Amgen Inc. (NASDAQ:AMGN). The firm published a detailed review of the Sjogren’s syndrome therapeutic development environment in advance of Amgen’s CD40 ligand-directed fusion protein dazodalibep’s Phase III conclusion […]
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand, which has supported the industry’s returns lately - over the past six months, healthcare stocks have gained 7.6%, nearly mirroring the S&P 500.
7.50am: 3i reveals slower growth for Action 3i Group said its largest portfolio company, Action, remains on track for a good second quarter despite like-for-like sales growth slowing. Ahead of its annual general meeting on Thursday, the FTSE 100-listed private equity investor said European...
In the most recent trading session, Amgen (AMGN) closed at $351.93, indicating a +1.42% shift from the previous trading day.
We recently compiled a list of the 10 Best Weight Loss Drug Stocks to Buy in 2026. Amgen Inc. (NASDAQ:AMGN) is one of the best weight loss drugs on this list. TheFly reported on June 16 that Mizuho analyst Salim Syed increased the price target for AMGN to $303 from $295 while maintaining a Neutral rating on […]
Weigh the financial strength of a pharma leader against the rapid growth, and risks, of a biotech newcomer as both navigate industry headwinds.
The iShares Nasdaq Biotechnology ETF (IBB) is trading just 1.47% below its 52-week high, signaling a potential multi-year sector breakout.
AMGN's biosimilars business is driving growth, with new launches and a deep pipeline helping offset patent losses in key branded drugs.
They look well-positioned to grab a slice of the fast-growing anti-obesity market.
In June 2026, a Delaware jury ruled that Amgen and its subsidiary Teneobio willfully infringed Harbour BioMed’s Grosveld patent, awarding Harbour US$20,203,704 in damages with the option to seek a tripling of that amount. The verdict, in one of the most closely watched antibody technology patent disputes, highlights legal and financial exposure around Amgen’s antibody discovery platforms and broader IP posture. We’ll now examine how this willful infringement verdict and potential higher...
Yahoo Finance Senior Reporter Brooke DiPalma joins Josh Lipton in highlighting the day's biggest stories and stock moves, including AbbVie's (ABBV) $10.9 billion acquisition of Apogee Therapeutics (APGE) and Coca-Cola's (KO) latest legal showdown with the IRS in US appeals court.
US futures were pointing higher at the start of the week as investors return from the Juneteenth holiday weekend, with technology stocks expected to lead gains despite lingering uncertainty over the Middle East and the prospect of further Federal Reserve tightening. Dow Jones futures were up...
Amgen posts strong profits and cash flow, while NovoCure pursues growth with a direct-to-patient cancer therapy model and leaner balance sheet.
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Amgen's (AMGN) well diversified business with no specific product driving over 10% of the top-line,
The latest trading day saw Amgen (AMGN) settling at $341.66, representing a -1.78% change from its previous close.
Like Lundbeck’s bocunebart, Vedana’s clinical pipeline targets PACAP – an approach that has shown varying levels of success in clinical trials thus far.
Management once made manufacturing its top priority; now that the topic has gone quiet, it reveals just how much the company's multi-billion-dollar bet has fundamentally changed.
With an annual dividend yield of 2.85%, Amgen Inc. (NASDAQ:AMGN) is included among the 12 High Yield Fortune 500 Stocks to Buy Now. Amgen Inc. (NASDAQ:AMGN) discovers, develops, manufactures, and delivers innovative medicines to fight some of the world’s toughest diseases. On June 10, Morgan Stanley analyst Terence Flynn raised the firm’s price target on […]
European Commission approves Amgen’s IMDYLLTRA for extensive stage small cell lung cancer, opening a new targeted immunotherapy option for patients in the region. FDA proposes withdrawing Tavneos from the U.S. market over data integrity and safety concerns, including reports of patient deaths. Amgen, NasdaqGS:AMGN, initiates an independent review with the Duke Clinical Research Institute to respond to the FDA’s findings and protect its autoimmune franchise. For investors watching...